Bristol, Pharmasset To Study Oral HCV Regimen Together
Partnership to study Bristol's NS5A inhibitor with Pharmasset's polymerase inhibitor is the first cross-company collaboration to study two oral agents in hepatitis C.
Partnership to study Bristol's NS5A inhibitor with Pharmasset's polymerase inhibitor is the first cross-company collaboration to study two oral agents in hepatitis C.